Biosimilar challenges include complex manufacturing processes and regulatory obstacles, offset by less regulated market ...

Researchers have found in a new research that HLA-B27 genetic marker is linked to a higher risk of various arthropathies, ...

Tofidence is indicated in certain patients for the treatment of moderate to severe rheumatoid arthritis, giant cell arteritis ...

Bio-Thera Solutions, the developer of the biosimilar, will continue to hold manufacturing rights in the US market.

Patients with juvenile idiopathic arthritis (JIA) who carried the HLA-B27 genetic marker tended to have worse long-term ...

One of the worst complications of adult-onset Still's disease is macrophage activation syndrome (MAS), which can be fatal. In ...

HLA-B27 positivity is linked to higher odds of non-remission in patients with juvenile idiopathic arthritis at 18 years after ...

Indian paediatric rheumatologists discuss early diagnosis and management of rheumatic disorders in children to prevent organ ...

Organon (OGN) announced that it has acquired from Biogen (BIIB) regulatory and commercial rights in the U.S. for Tofidence, a biosimilar to ...

Organon (OGN) stock in focus as the Merck (MRK) spinoff buys rights to Biogen's (BIIB) biosimilar Tofidence, targeting ...